protease inhibitors — Competitive Intelligence Brief

protease inhibitors (protease inhibitors) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease inhibitor. Area: Infectious Disease / Virology.

marketed Protease inhibitor HIV protease Infectious Disease / Virology Small molecule

Target snapshot

protease inhibitors (protease inhibitors) — French National Agency for Research on AIDS and Viral Hepatitis. Protease inhibitors block the activity of viral proteases, preventing the cleavage of viral polyproteins necessary for viral replication and maturation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
protease inhibitors TARGET	protease inhibitors	French National Agency for Research on AIDS and Viral Hepatitis	marketed	Protease inhibitor	HIV protease
Darunavir (DRV/r)	Darunavir (DRV/r)	Community Research Initiative of New England	marketed	HIV protease inhibitor	HIV protease
Lopinavir / Ritonavir	Lopinavir / Ritonavir	Baqiyatallah Medical Sciences University	marketed	HIV protease inhibitor	HIV protease
Maraviroc, Darunavir/r	Maraviroc, Darunavir/r	Catholic University of the Sacred Heart	marketed	Antiretroviral combination (CCR5 antagonist + protease inhibitor)	CCR5 co-receptor (maraviroc); HIV protease (darunavir)
Darunavir/r	Darunavir/r	Juan A. Arnaiz	marketed	HIV protease inhibitor	HIV protease
ATV/r	ATV/r	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	HIV protease inhibitor (boosted)	HIV protease
Atazanavir/ Stavidine / Lamivudine	Atazanavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Protease inhibitor class)

1. Pfizer · 4 drugs in this class
2. French National Agency for Research on AIDS and Viral Hepatitis · 4 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. Christopher J. McLeod · 1 drug in this class
5. Hoffmann-La Roche · 1 drug in this class
6. Janssen R&D Ireland · 1 drug in this class
7. Janssen-Cilag International NV · 1 drug in this class
8. Johns Hopkins University · 1 drug in this class
9. Medical Research Council · 1 drug in this class
10. Pfizer Inc. · 1 drug in this class